Recardio, Inc.   Report issue

For profit Phase 3
Founded: San Francisco CA United States (2011)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03486080
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Recardio, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

dutogliptin (2 trials)

Filgrastim (neupogen) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 2)

Ischemia (Phase 2)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2